What were the key financial results for Biome (ASX:BIO) in H1 FY26?

Biome reported a record net profit of $1.2 million for the first half of FY26, marking a 172% increase compared to the previous year. This growth was supported by record half-year sales revenue of $12.4 million, which is an approximate 40% jump over the prior corresponding period.

Is Biome (ASX:BIO) currently profitable and generating positive cash flow?

Yes, Biome has achieved its eighth consecutive quarter of positive EBITDA, reaching a record $1.5 million for H1 FY26. The company’s transition into sustained profitability is reflected in its 172% net profit growth and an annualised revenue run rate now sitting at approximately $25.8 million.

How has Biome (ASX:BIO) managed its debt and balance sheet recently?

Biome strengthened its balance sheet by reducing its total borrowings from $2.91 million down to $1.5 million. This 48% reduction in debt, combined with rising revenues, lowers the company’s financial risk profile and provides more flexibility for future operations.

What are the main growth drivers for Biome’s revenue increase?

The 40% revenue surge was driven by expanding distribution and strong sales performance across its probiotic and health product lines. Key domestic partnerships with Mecca and Go Vita.

What is the significance of the new warehouse facility in Brunswick?

Biome secured a 1,350sqm warehouse in Victoria to provide 500 additional pallet positions, which essential for managing its increasing inventory requirements.

What is the current status of Biome’s clinical research and R&D?

Biome has received ethics approval to begin its first human clinical trial for its proprietary BMB18 strain in partnership with La Trobe University.

How is Biome (ASX:BIO) expanding its international footprint?

The company has entered the North American market by securing a distribution partnership with Fullscript in Canada. This move indicates a strategic pivot toward international markets to complement its Australian pharmacy and retail presence.

What are the bull and bear points for Biome (ASX:BIO) after these results?

The bull case focuses on the triple-digit profit growth, debt reduction, and successful expansion into new distribution channels like Mecca. The bear case would monitor whether the company can maintain these high growth rates as it scales globally and manages the increased overhead of its new, larger warehouse facility.

Image for illustrative purposes only. Not a real photo.

Biome books record H1 profit growth

Written by Heidi Cuthbert Published Feb 23, 2026, 2:55 AMLast Updated Jul 6, 2026, 10:45 AM

Biome (ASX:BIO) has delivered its performance for the first half of FY26, headlined by a net profit of $1.2 million, a 172% increase over the previous year.

The financial surge was driven by record half-year sales revenue of $12.40 million—up approximately 40%—and a record EBITDA of $1.47 million, marking the company's eighth consecutive quarter of positive earnings.

The company’s fiscal health is further bolstered by an annualized revenue run rate of $25.8 million and a significant reduction in debt, with borrowings slashed from $2.91 million to $1.50 million.

Beyond the balance sheet, Biome has solidified its position as the fastest-growing probiotic brand in Australian community pharmacies, with its entire product range currently in growth.

The company is scaling rapidly through high-profile distribution partnerships with Fullscript in Canada, as well as Mecca and Go Vita domestically.

To support this trajectory, Biome secured a new 1,350sqm warehouse in Brunswick, Victoria, adding 500 pallet positions to its logistics network.

The company also continues to invest in its clinical foundations, receiving ethics approval for its first human clinical trial on the proprietary BMB18 strain in collaboration with La Trobe University.

At the time of reporting, Biome's share price was $0.42.

Biome books record H1 profit growth

Frequently asked questions

Assets related to this article